Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.

The pharmacogenomics journal - 1 Jun 2021

van Eijk Maarten, Pluim Dick, Dorlo Thomas P C, Marchetti Serena, Huitema Alwin D R, Beijnen Jos H

Abstract excerpt

The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability. In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the pharmacokinetics and pharmacodynamics of oral docetaxel, co-administered with ritonavir. None of the tested CYP3A, ABCB1, ABCC2, and SLCO1B3 genotypes and diplotypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Antineoplastic Agents, Phytogenic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Biological Availability

Share to Carcinoma, Non-Small-Cell Lung

Share to Docetaxel

Share to Pharmacogenetics

Share to Ritonavir

Source

Identifiers

PMID: 33649517
DOI: 10.1038/s41397-021-00213-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.PMID 33649517Read ↗

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.Semantic proximity Read ↗

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.Semantic proximity Read ↗

Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.Semantic proximity Read ↗

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.Semantic proximity Read ↗

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.Semantic proximity Read ↗

Pharmacogenetic pathway analysis of docetaxel elimination.Semantic proximity Read ↗

Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.Semantic proximity Read ↗

Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphismsSemantic proximity Read ↗

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.Semantic proximity Read ↗

Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients.Semantic proximity Read ↗

Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Semantic proximity Read ↗

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.